Perlecan from human epithelial cells is a hybrid heparan/chondroitin/keratan sulfate proteoglycan |
| |
Authors: | Knox S Fosang A J Last K Melrose J Whitelock J |
| |
Affiliation: | Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, MN 55455, USA. |
| |
Abstract: | ![]() Perlecan is a multidomain proteoglycan, usually substituted with heparan sulphate (HS), and sometimes substituted with both HS and chondroitin sulphate (CS). In this paper, we describe perlecan purified from HEK-293 cells substituted with HS, CS and keratan sulphate (KS). KS substitution was confirmed by immunoreactivity with antibody 5D4, sensitivity to keratanase treatment, and fluorophore-assisted carbohydrate electrophoresis. HEK-293 perlecan failed to promote FGF-dependent cell growth in an in vitro assay. This study is the first to report perlecan containing KS, and makes perlecan one of only a very few proteoglycans substituted with three distinct types of glycosaminoglycan chains. |
| |
Keywords: | HUAEC, human umbilical arterial endothelial cell HEK-293, human embryonic kidney cell line FACE, fluorophore assisted carbohydrate electrophoresis EβG, endo-β-galactosidase |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|